Top row: Erik van den Berg, Peter Verwayen, Jacques Arend,
Bart Wuurman
Bottom row: Markwin Velders, Steve Connor
Chief Executive Officer
Drs. Bart Wuurman has 18 years of International Pharma and Biotechnology Industry
experience with Organon, Medeva and Antisoma, where he was Business Development
Director and member of the executive team. At Antisoma, Bart was responsible
for a $500 million oncology alliance with Roche. In 2003 Bart became CEO of
De Novo Pharmaceuticals in Cambridge, UK, where he was responsible for the successful
restructuring and refinancing of the company.
VP Corporate Development
Erik van den Berg MSc MBA, has over ten years experience in the pharmaceutical
and biotech industry. During his employment at Organon he was responsible for
the European business development, the European marketing & sales of biotechnology
services and in his last position he was leading the global biotech business
development efforts. Prior to joining Organon, he worked in business and corporate
development with the biotech company IsoTis and as management consultant at
Arthur D. Little. Erik has been involved in the execution of over 20 transactions
and partnerships.
VP Clinical Development
Jacques Arend, MD joined the pharmaceutical industry in 1988, in medical
and clinical development positions. He started at SmithKline Beecham, and then
became international coordinator clinical development with Yamanouchi Pharma’s
European office. He was medical director for Novo Nordisk, where he subsequently
held three international positions as director medical, regulatory and quality
based in Austria, Greece and Switzerland, with responsibility over the largest
geographical region in Novo Nordisk, setting up clinical studies in Europe,
Latin America, Eastern Europe, India, China, South Africa, North Africa and
Gulf region, the Far and Middle East. After his return to The Netherlands Jacques
became medical director for Grünenthal. Most recently he was the medical
director for Kendle’s phase one 50 beds Clinical Pharmacology Unit in
Utrecht. Prior to his positions in the pharmaceutical industry Jacques was a
clinical research physician, followed by a SHO position in Surgery.
VP Pre-Clinical Development
After graduating in microbiology, Steve worked at the Withington Hospital,
Manchester UK from 1978-1985. He then held increasingly senior positions in
Cambridge, UK at Murex Medical Research Ltd, Quantum Biosystems Ltd, Cantab
Pharmaceuticals Research Ltd, Chiroscience R&D Ltd, and Imutran Ltd, a Novartis
Pharma company where Steve was appointed Director of Development. Steve joined
pSiMedica Ltd, a start up company in November 2001 as Director of Development
establishing operational activities across Europe and Asia. Steve joined AM-Pharma
as VP Pre-Clinical Development in July 2007. Steve Connor is an experienced
manager with extensive knowledge of the pharmaceutical and biological industries,
including the management of R&D and manufacturing operations for both early
and late phase clinical trial supply. He has wide practical experience of contract
product development and production throughout Europe, Asia and the USA, working
in both large and start-up company environments.
VP Finance
Peter Verwaijen gained most of his experience during the 16 years that he worked
as controller for Atlas Venture, a transatlantic Venture Fund. More recently
he worked as controller for Glaucus Proteomics, a Dutch biotech start-up company.